Coloplast A/S is set to acquire Uromedica, enhancing its offerings in the urology segment and aligning with its strategic growth objectives in chronic care.

Information on the Target

Coloplast A/S, a leading global medical device company headquartered in Denmark, specializes in developing products that enhance the quality of life for individuals with intimate health needs. Established in 1954, the company is recognized for its innovative solutions in five primary business areas: Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology. Coloplast's commitment to improving the lives of its customers has helped it build a strong market presence across various countries.

The recent interim financial report for Q1 2025/26 highlights Coloplast's solid growth trajectory, reporting an organic growth of 6% and a stable EBIT growth in constant currencies of 3%. This growth is attributed to various factors, including a robust contribution from its Continence Care and Interventional Urology segments, although challenges in Ostomy Care and the Kerecis business unit were noted.

Industry Overview in Denmark

The medical device industry in Denmark is recognized as one of the most innovative globally, fostering numerous advancements in healthcare technology. Denmark is home to established medical device manufacturers and new startups alike, thanks to i